Tom 8, Supl. E (2022)
Artykuł redakcyjny
Opublikowany online: 2023-05-19
Wyświetlenia strony
73
Wyświetlenia/pobrania artykułu
12
Wprowadzenie
Streszczenie
Brak
Referencje
- Rutkowski P, Wysocki PJ, Kozak K, et al. Expert recommendations on diagnostic-therapeutic management of melanoma patients. . Oncol Clin Pract. 2021: 0042.
- Rutkowski R. Nowe terapie systemowe u chorych na nowotwory skóry. Via Medica, Gdańsk 2022.
- Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017; 28(7): 1631–1639.
- Long GV, Grob JJ, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016; 17(12): 1743–1754.
- Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019; 381(7): 626–636.
- Davies M, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. The Lancet Oncology. 2017; 18(7): 863–873.
- Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017; 377(19): 1813–1823.
- Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected V600-mutant stage III melanoma. J Clin Oncol. 2018; 36(35): 3441–3449.
